Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul;27(7):581-585.
doi: 10.1111/tbj.14233. Epub 2021 Apr 18.

Can one stop nucleic acid sampling (OSNA) predict nodal positivity following neoadjuvant chemotherapy? A prospective cohort study of 293 patients

Jeremy Batt  1 , Timothy Schrire  1 , Zenon Rayter  1
Affiliations

Can one stop nucleic acid sampling (OSNA) predict nodal positivity following neoadjuvant chemotherapy? A prospective cohort study of 293 patients

Jeremy Batt et al. Breast J. 2021 Jul.

Abstract

Until recently, axillary node clearance had long been the standard of care in patients with axillary node-positive disease. One stop nucleic acid sampling (OSNA) has been used to guide intraoperative decision-making regarding suitability for axillary node clearance (ANC). The aim of this study is to evaluate the use of OSNA following neoadjuvant chemotherapy (NACT) and whether it can predict lymph node burden in ANC. A single center, prospective cohort study was performed on 297 patients having OSNA between 2016 and 2019. Patients were sub-classified according to node positivity at diagnosis and those treated with NACT and outcomes included copy number and lymph node harvest. Axillary complete pathological response was observed in 24/36 patients (67%) following NACT. 14/16 patients (87%) having axillary node clearance had axillary node disease limited to 4 nodes. OSNA copy numbers were significantly higher in patients showing disease progression following NACT. Overall, 73% of patients with lymph node positivity at diagnosis could be successfully treated with a combination of NACT and lymph node excision of four nodes. De-escalating axillary surgical treatment to resection of four nodes following NACT may be effective in balancing oncological resection and limiting treatment morbidity. ONSA can correctly identify patients experiencing disease progression who would benefit from traditional three-level ANC.

Keywords: OSNA; axillary node clearance; breast cancer; complete pathological response; neoadjuvant chemotherapy.

PubMed Disclaimer

References

REFERENCES

    1. Geng C, Chen X, Pan X, Li J. The feasibility and accuracy of sentinel lymph node biopsy in initially clinically node negative breast cancer after neoadjuvant chemotherapy: a systematic review and meta-analysis. PLoS One. 2016;11:e0162605.
    1. Goyal A, Dodwell D. POSNOC: a randomised trial looking at axillary treatment in women with one or two sentinel nodes with macrometastases. Clin Oncol. 2015;27(12):692-695.
    1. Gandhi A, Coles C, Makris A, et al. Axillary surgery following neoadjuvant chemotherapy e multidisciplinary guidance from the association of breast surgery, faculty of clinical oncology of the royal college of radiologists, UK breast cancer group, national coordinating committee for breast pathology and British Society of breast radiology. Clin Oncol (R Coll Radiol). 2019;31:664-668.
    1. Morgan C, Stringfellow TD, Rolph R, et al. Neoadjuvant chemotherapy in patients with breast cancer: does response in the breast predict axillary node response?. Eur J Surg Oncol. 2020;46(4 Pt A):522-526.
    1. Mamounas EP. Optimizing surgical management of the axilla after neoadjuvant chemotherapy: an evolving story. Ann Surg Oncol. 2018;25(8):2124-2126.

LinkOut - more resources